Description
Key facts
Cell type:HEK-293T,
Species or organism:Human,
Tissue:Kidney,
Form:LiquidSee storage information,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 2 and 20 bp deletion in exon 2
Product details:
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-B4GALT2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Shipped at conditions-Dry Ice, Appropriate short-term storage conditions--196°C, Appropriate long-term storage conditions--196°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
B4GALT2 also known as UDP-Gal:betaGlcNAc beta 14- galactosyltransferase polypeptide 2 is an enzyme involved in the glycosylation process. It has a molecular weight of about 41 kDa. You can find B4GALT2 in various tissues including liver kidney and heart. The enzyme transfers galactose to N-acetylglucosamine forming N-acetyllactosamine structures which are important in the synthesis of glycoproteins and glycolipids.
Biological function summary
The enzyme plays a role in critical cellular functions by participating in cell surface glycan formation. It is part of the galactosyltransferase family and works as a single polypeptide chain. B4GALT2 adds galactose residues in a beta 14 linkage on glycoproteins and glycolipids in the Golgi apparatus. This modification helps in cell communication and molecule stability.
Pathways
The B4GALT2 enzyme functions in the glycosylation pathway especially in the N-linked glycosylation process. It interacts with other enzymes like B4GALT1 and B4GALT3 involved in the same pathway. Both perform similar roles but work on different substrates or in different contexts in the cell contributing to the diversity of glycan structures seen in organisms.
B4GALT2 influences cancer progression and congenital disorders of glycosylation. Altered expression or function of B4GALT2 has been associated with tumor metastasis and progression particularly in breast cancer. Additionally mutations in B4GALT2 can lead to congenital disorders affecting glycoprotein modification and function. The protein interacts with other enzymes such as GALNTs in these disease contexts influencing their pathology and outcomes.
